Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

doi:10.1002/cam4.4182

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Cancer medicine - 1 Sept 2021

de Botton Stéphane, Brandwein Joseph M, Wei Andrew H, Pigneux Arnaud, Quesnel Bruno, Thomas Xavier, Legrand Ollivier, Recher Christian, Chantepie Sylvain, Hunault-Berger Mathilde, Boissel Nicolas, Nehme Salem A, Frattini Mark G, Tosolini Alessandra, Marion-Gallois Roland, Wang Jixian J, Cameron Chris, Siddiqui Muhaimen, Hutton Brian, Milkovich Gary, Stein Eytan M

Abstract excerpt

BACKGROUND: The present study evaluated the relative survival benefits associated with enasidenib and current standard of care (SoC) therapies for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT). METHODS: Propensity score matching (PSM) analysis compared survival outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials, Phase I as Topic

Share to Clinical Trials, Phase II as Topic

Share to Isocitrate Dehydrogenase

Share to Multicenter Studies as Topic

Share to Observational Studies as Topic

Share to Propensity Score

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 34427990
DOI: 10.1002/cam4.4182
PMCID: PMC8446562

Genes

IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.PMID 34427990Read ↗

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.Semantic proximity Read ↗

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Semantic proximity Read ↗

Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.Semantic proximity Read ↗

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.Semantic proximity Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.Semantic proximity Read ↗

Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.Semantic proximity Read ↗

Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis.Semantic proximity Read ↗

Enasidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.